Peanut Allergy Clinical Trial
Official title:
Oral Peanut Immunotherapy
Peanut allergy is one of the most serious food allergies because of its life long persistence, and the potential for severe allergic reactions. Effective oral immunotherapy would benefit patients by reducing the likelihood that they will have life-threatening accidental allergic reactions. This research study is being done to develop an effective oral immunotherapy treatment for patients with peanut allergy.
Our hypothesis is that chronic antigen exposure during peanut oral immunotherapy (OIT) will
induce beneficial changes in the specific immune response, including: 1) anergy of IgE
effector immune cells (e.g., mast cells, basophils) resulting in clinical desensitization; 2)
induction of de novo, long lived (memory) B cell responses that antagonize specific IgE and
confer immune tolerance. The investigators will test this hypothesis in the following
specific aims:
1. Induce desensitization in peanut allergic subjects with peanut OIT and evaluate the
safety of the peanut OIT desensitization protocol.
2. Induce long-standing tolerance in peanut allergic subjects with maintenance peanut OIT
and evaluate the efficacy of allergen-specific testing to predict tolerance.
3. Longitudinally evaluate basophil and mast cell reactivity in subjects receiving peanut
OIT and their relationship to the induction of desensitization.
4. Longitudinally evaluate the allergen-specific B-cell repertoire in subjects receiving
peanut OIT and its relationship to the induction of tolerance.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05667610 -
Immune-supportive Diet and Gut Permeability in Allergic Children
|
N/A | |
| Recruiting |
NCT05440643 -
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
|
Phase 1 | |
| Terminated |
NCT03849079 -
Validation of the HYPONUT Product
|
N/A | |
| Completed |
NCT02979600 -
Clinical and Biological Efficacy of Peanut Oral Immunotherapy
|
N/A | |
| Completed |
NCT01955109 -
Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children
|
Phase 2 | |
| Completed |
NCT01950533 -
The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
|
||
| Recruiting |
NCT04415593 -
High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety
|
N/A | |
| Active, not recruiting |
NCT04511494 -
Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT
|
N/A | |
| Active, not recruiting |
NCT04887441 -
Allergology: Information, Data and Knowledge Organization
|
||
| Active, not recruiting |
NCT04881773 -
Oral Low Doses Tolerance INduction Study for Peanuts
|
||
| Completed |
NCT03682770 -
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
|
Phase 2 | |
| Terminated |
NCT03703791 -
Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents
|
Phase 3 | |
| Completed |
NCT02916446 -
Safety Study of Viaskin Peanut to Treat Peanut Allergy
|
Phase 3 | |
| Active, not recruiting |
NCT02402231 -
Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy
|
Phase 2 | |
| Completed |
NCT03337542 -
AR101 Real-World Open-Label Extension Study
|
Phase 3 | |
| Recruiting |
NCT05476497 -
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
|
Phase 1 | |
| Completed |
NCT03648320 -
The Grown Up Peanut Immunotherapy Study
|
N/A | |
| Completed |
NCT03292484 -
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
|
Phase 3 | |
| Completed |
NCT03852342 -
Reactive Doses and Times During Oral Food Challenge to Peanut
|
||
| Recruiting |
NCT05138757 -
Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy
|
Phase 1/Phase 2 |